Crossmark

Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis

Crossref DOI link: https://doi.org/10.1007/s12325-021-01708-8

Published Online: 2021-05-05

Published Print: 2021-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pozo-Rosich, Patricia

Samaan, Karen H. https://orcid.org/0000-0003-2780-9232
Schwedt, Todd J.

Nicholson, Robert A.

Rettiganti, Mallikarjuna

Pearlman, Eric M.
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02614183 at ClinicalTrials.gov

Documents that mention this clinical trial

Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis
https://doi.org/10.1007/s12325-021-01708-8

Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
https://doi.org/10.1007/s12325-021-01848-x

nct02614196 at ClinicalTrials.gov

Documents that mention this clinical trial

Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis
https://doi.org/10.1007/s12325-021-01708-8

Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
https://doi.org/10.1007/s12325-021-01848-x

nct02614261 at ClinicalTrials.gov

Documents that mention this clinical trial

Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis
https://doi.org/10.1007/s12325-021-01708-8

Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
https://doi.org/10.1007/s12325-021-01848-x

Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)
https://doi.org/10.1007/s11136-020-02623-1
Funding

Funding for this research was provided by:

Eli Lilly and Company
License Information

Text and Data Mining valid from 2021-05-05

Version of Record valid from 2021-05-05
More Information

Article History

Received: 9 December 2020

Accepted: 12 March 2021

First Online: 5 May 2021

Document is current

Any future updates will be listed below